Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat ...

The study met its primary endpoint with a statistically significant and clinically meaningful reduction in pain on the numeric pain rating scale (NPRS). The suzetrigine arm showed a statistically ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...

The primary endpoint was the within-group change from baseline in the weekly average of daily leg pain intensity on a numeric pain rating scale (NPRS) at Week 12. The study also included a placebo ...

Suzetrigine, an oral, highly selective NaV1.8 pain signal inhibitor, showed statistically significant and clinically meaningful reduction in pain on the numeric pain rating scale (NPRS ...

A further 100 people received placebo. However, the primary endpoint looked at the change on the numeric pain rating scale (NPRS) from baseline, not compared to placebo. That allowed the trial to ...

The primary endpoint was the within-group change from baseline in the weekly average of daily leg pain intensity on a numeric pain rating scale (NPRS) at Week 12. The study also included a placebo ...

Placebo showed a reduction of -1.98 in the numeric pain rating scale or NPRS, while Suzetrigine recorded -2.02 on NPRS. The company said the results met primary endpoint with meaningful reduction ...

However, the placebo reference arm "showed a similar within-group reduction from baseline in pain with a mean change in NPRS at Week 12 of -1.98," Vertex said. It added that "the study was not ...